Luis G. Paz-Ares, MD, PhD, on Extensive-Stage SCLC: Comparison of First-Line Regimens
2025 ASCO Annual Meeting
Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, discusses data from the TIGOS trial, a phase III study comparing the first-line use of atigotatug (an antifucosyl-GM1 monoclonal antibody) plus nivolumab fixed-dose combination with chemotherapy vs atezolizumab with chemotherapy in patients with extensive-stage small cell lung cancer (SCLC) (Abstract TPS8127).
The ASCO Post Staff
Raffaele Califano, MD, of the Christie NHS Foundation Trust and the University of Manchester, discusses outcomes by osimertinib resistance mechanisms in MARIPOSA-2, a study that evaluated the efficacy of the bispecific antibody amivantamab-vmjw plus chemotherapy vs chemotherapy in patients with EGFR-mutant advanced NSCLC after disease progression on osimertinib (Abstract 8639).
The ASCO Post Staff
Frank A. Sinicrope, MD, of Mayo Clinic Rochester, reviews findings from the randomized Alliance A021502/ATOMIC trial, which studied standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III DNA mismatch repair–deficient (dMMR) colon cancer (LBA1).
The ASCO Post Staff
David Allen Barbie, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, reviews specific clinical and molecular features of early progressors and long-term progression-free survivors from the phase III ADRIATIC trial, which assessed consolidation durvalumab vs placebo after concurrent chemoradiotherapy for limited-stage small cell lung cancer (Abstract 8014).
The ASCO Post Staff
Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, discusses the sensitivity of age and family history criteria for determining eligibility for pancreatic cancer surveillance among individuals with a hereditary risk for the malignancy (Abstract 10500).
The ASCO Post Staff
Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, IRCCS, University of Milano, discusses patient-reported outcomes from the phase III EMBER-3 trial, which investigated treatment with imlunestrant, investigator’s choice of standard endocrine therapy, or imlunestrant plus abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer (Abstract 1001).
